Literature DB >> 20847038

Bradykinin-induced lung inflammation and bronchoconstriction: role in parainfluenze-3 virus-induced inflammation and airway hyperreactivity.

Kenneth J Broadley1, Alan E Blair, Emma J Kidd, Joachim J Bugert, William R Ford.   

Abstract

Inhaled bradykinin causes bronchoconstriction in asthmatic subjects but not nonasthmatics. To date, animal studies with inhaled bradykinin have been performed only in anesthetized guinea pigs and rats, where it causes bronchoconstriction through sensory nerve pathways. In the present study, airway function was recorded in conscious guinea pigs by whole-body plethysmography. Inhaled bradykinin (1 mM, 20 s) caused bronchoconstriction and influx of inflammatory cells to the lungs, but only when the enzymatic breakdown of bradykinin by angiotensin-converting enzyme and neutral endopeptidase was inhibited by captopril (1 mg/kg i.p.) and phosphoramidon (10 mM, 20-min inhalation), respectively. The bronchoconstriction and cell influx were antagonized by the B(2) kinin receptor antagonist 4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido]-tetrahydro-2H-4-pyranylcarbonyl}piperazino)-5-oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132) when given by inhalation (1 and 10 μM, 20 min) and are therefore mediated via B(2) kinin receptors. However, neither intraperitioneal MEN16132 nor the peptide B(2) antagonist icatibant, by inhalation, antagonized these bradykinin responses. Sensitization of guinea pigs with ovalbumin was not sufficient to induce airway hyperreactivity (AHR) to the bronchoconstriction by inhaled bradykinin. However, ovalbumin challenge of sensitized guinea pigs caused AHR to bradykinin and histamine. Infection of guinea pigs by nasal instillation of parainfluenza-3 virus produced AHR to inhaled histamine and lung influx of inflammatory cells. These responses were attenuated by the bradykinin B(2) receptor antagonist MEN16132 and H-(4-chloro)DPhe-2'(1-naphthylalanine)-(3-aminopropyl)guanidine (VA999024), an inhibitor of tissue kallikrein, the enzyme responsible for lung synthesis of bradykinin. These results suggest that bradykinin is involved in virus-induced inflammatory cell influx and AHR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847038     DOI: 10.1124/jpet.110.171876

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Airway Vagal Neuroplasticity Associated with Respiratory Viral Infections.

Authors:  Eric J Zaccone; Bradley J Undem
Journal:  Lung       Date:  2015-12-17       Impact factor: 2.584

2.  Pharmacology of Bradykinin-Evoked Coughing in Guinea Pigs.

Authors:  Matthew M Hewitt; Gregory Adams; Stuart B Mazzone; Nanako Mori; Li Yu; Brendan J Canning
Journal:  J Pharmacol Exp Ther       Date:  2016-03-21       Impact factor: 4.030

3.  Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19.

Authors:  Tanja Gangnus; Bjoern B Burckhardt
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

4.  Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors.

Authors:  Sharton V A Coelho; Naiara M Rust; Lucas Vellasco; Michelle P Papa; Aline S G Pereira; Matheus Ferreira da Silva Palazzo; Maria Aparecida Juliano; Simone M Costa; Ada M B Alves; Marli T Cordeiro; Ernesto T A Marques; Júlio Scharfstein; Luciana B de Arruda
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-12

5.  Mass spectrometric study of variation in kinin peptide profiles in nasal fluids and plasma of adult healthy individuals.

Authors:  Tanja Gangnus; Anke Bartel; Bjoern B Burckhardt
Journal:  J Transl Med       Date:  2022-03-29       Impact factor: 5.531

6.  Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19.

Authors:  Azadeh Khalili; Hosein Karim; Gholamreza Bayat
Journal:  Iran J Med Sci       Date:  2021-07

Review 7.  A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).

Authors:  Maryam Rameshrad; Majid Ghafoori; Amir Hooshang Mohammadpour; Mohammad Javad Dehghan Nayeri; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-05-19       Impact factor: 3.000

8.  Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?

Authors:  Simone Meini; Andrea Zanichelli; Rodolfo Sbrojavacca; Federico Iuri; Anna Teresa Roberts; Chiara Suffritti; Carlo Tascini
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

9.  Clinical and daily respiratory care and clinical trials within the COVID-19 era.

Authors:  Zuzana Diamant; Vibeke Backer; Leif Bjermer
Journal:  Eur Clin Respir J       Date:  2020-05-25

10.  Preventing acute asthmatic symptoms by targeting a neuronal mechanism involving carotid body lysophosphatidic acid receptors.

Authors:  Nicholas G Jendzjowsky; Arijit Roy; Nicole O Barioni; Margaret M Kelly; Francis H Y Green; Christopher N Wyatt; Richard L Pye; Luana Tenorio-Lopes; Richard J A Wilson
Journal:  Nat Commun       Date:  2018-10-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.